2026年11月5日星期四
M
Meridian Globe
သတင်းအမြန်
APEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaJapan regional banks form united front on cybersecurity— 日经 Nikkei AsiaThe best is yet to come: Asia's chance to reimagine AI— 日经 Nikkei AsiaUS tech giants' hidden AI debt swells 90% to $3.2tn in 6 months— 日经 Nikkei AsiaFukushima tries to reinvent itself as hub for drones, robots and rockets— 日经 Nikkei AsiaJapan's Yamato targets 'leaner' delivery service in push for profit: president— 日经 Nikkei AsiaNew MUFG digital bank to forgo ATM cards in cybercrime safeguard— 日经 Nikkei AsiaJapan to bolster defenses with unified missile, artillery systems— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaJapan regional banks form united front on cybersecurity— 日经 Nikkei AsiaThe best is yet to come: Asia's chance to reimagine AI— 日经 Nikkei AsiaUS tech giants' hidden AI debt swells 90% to $3.2tn in 6 months— 日经 Nikkei AsiaFukushima tries to reinvent itself as hub for drones, robots and rockets— 日经 Nikkei AsiaJapan's Yamato targets 'leaner' delivery service in push for profit: president— 日经 Nikkei AsiaNew MUFG digital bank to forgo ATM cards in cybercrime safeguard— 日经 Nikkei AsiaJapan to bolster defenses with unified missile, artillery systems— 日经 Nikkei Asia

[Articles] Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial

ရင်းမြစ် 柳叶刀 Lancetလွန်ခဲ့သော 11 ရက်
Summary

Mitapivat, an oral pyruvate kinase activator, with a novel mechanism that ameliorates haemolytic anaemia, has the potential to be an effective and convenient d…

ကျွန်ုပ်တို့သည် ခေါင်းစဉ်နှင့် အနှစ်ချုပ် ညွှန်းကိန်းကိုသာ ပေးသည်။ အပြည့်အစုံနှင့် မူပိုင်ခွင့်သည် မူရင်းထုတ်ဝေသူထံတွင် ရှိသည် — မူရင်းလင့်ကို နှိပ်၍ ဖတ်ပါ။

မူရင်း ဖွင့်ရန်
ကဏ္ဍ
Health
ဒေသ
United Kingdom
Language
English
Item ID
health-94d31632

Comments 0 comments

No comments yet. Be the first.

[Articles] Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial · Meridian Globe